- Conditions
- Tardive Dyskinesia
- Interventions
- NBI-1065890, Placebo
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 18
- States / cities
- Bryant, Arkansas • Chino, California • Fountain Valley, California + 15 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Parkinson Disease
- Interventions
- Opicapone, Carbidopa Levodopa
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 3
- States / cities
- Glendale, California • Long Beach, California • Farmington Hills, Michigan
- Conditions
- Parkinson's Disease
- Interventions
- Not listed
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 14 participants
- Timeline
- 2018 – 2023
- U.S. locations
- 3
- States / cities
- San Francisco, California • Atlanta, Georgia • Columbus, Ohio
- Conditions
- Tardive Dyskinesia
- Interventions
- NBI-98854
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 43
- States / cities
- Anaheim, California • Glendale, California • Irvine, California + 40 more
- Conditions
- Idiopathic Parkinson's Disease, Parkinson's Disease, Basal Ganglia Disease, Brain Diseases, Central Nervous System Diseases, Movement Disorders, Nervous System Diseases, Neurodegenerative Diseases, Parkinsonian Disorders
- Interventions
- VY-AADC01
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 4
- States / cities
- San Francisco, California • Atlanta, Georgia • Columbus, Ohio + 1 more
- Conditions
- Safety, Tolerability, and PK of NBI-98854 in Hepatically Impaired Subjects
- Interventions
- NBI-98854 50 mg capsule
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 3
- States / cities
- Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota
- Conditions
- Schizophrenia
- Interventions
- Luvadaxistat, Placebo
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 16
- States / cities
- Garden Grove, California • Lemon Grove, California • Los Angeles, California + 13 more
- Conditions
- Healthy Volunteers
- Interventions
- TAK-831
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Lenexa, Kansas
- Conditions
- Tourette Syndrome
- Interventions
- Valbenazine, Placebo oral capsule
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 48
- States / cities
- Sun City, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 43 more
- Conditions
- Epileptic Encephalopathy, Continuous Spike and Wave During Sleep
- Interventions
- NBI-827104
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 4 Years to 12 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 7
- States / cities
- Orange, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more
- Conditions
- Healthy Volunteers
- Interventions
- TAK-831 Oral Tablet, [14C]TAK-831 IV Infusion, [14C]TAK-831 Oral Suspension
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 19 Years to 55 Years · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Major Depressive Disorder
- Interventions
- NBI-1065845, Placebo
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 24
- States / cities
- Oceanside, California • Orange, California • San Jose, California + 21 more
- Conditions
- Major Depressive Disorder
- Interventions
- Placebo, NBI-1065845
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Riverside, California + 14 more
- Conditions
- Tardive Dyskinesia, Intellectual Disability, Developmental Disabilities
- Interventions
- Valbenazine Oral Capsule
- Drug
- Lead sponsor
- Stephen Ruedrich
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Schizophrenia
- Interventions
- NBI-1117568, Placebo
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 21
- States / cities
- Bryant, Arkansas • Little Rock, Arkansas • Anaheim, California + 18 more
- Conditions
- Tardive Dyskinesia (TD)
- Interventions
- Valbenazine, Placebo oral capsule
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 42
- States / cities
- Little Rock, Arkansas • Anaheim, California • Costa Mesa, California + 35 more
- Conditions
- Tourette Syndrome
- Interventions
- Valbenazine, Placebo oral capsule
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 34
- States / cities
- Sun City, Arizona • Rogers, Arkansas • Anaheim, California + 27 more
- Conditions
- Healthy Volunteers, Schizophrenia
- Interventions
- TAK-041, TAK-041 Placebo
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Tourette Syndrome
- Interventions
- NBI-98854
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 10
- States / cities
- San Diego, California • Kissimmee, Florida • St. Petersburg, Florida + 7 more
- Conditions
- Chorea, Huntington
- Interventions
- Valbenazine, Placebo
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 37 more
- Conditions
- Schizophrenia
- Interventions
- NBI-1117568, Placebo
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 15
- States / cities
- Little Rock, Arkansas • Rogers, Arkansas • Lemon Grove, California + 12 more
- Conditions
- Tourette Syndrome
- Interventions
- Valbenazine
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 6 Years to 64 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 13
- States / cities
- Sun City, Arizona • San Diego, California • Loxahatchee Groves, Florida + 10 more
- Conditions
- Tardive Dyskinesia
- Interventions
- NBI-98854, Placebo
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 21
- States / cities
- Costa Mesa, California • Fountain Valley, California • Oceanside, California + 17 more
- Conditions
- Breast Cancer, Kidney Cancer, Lung Cancer
- Interventions
- interleukin-4 PE38KDEL cytotoxin
- Biological
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2008
- U.S. locations
- 2
- States / cities
- Tucson, Arizona • Los Angeles, California